Shifting the lines against central nervous system disorders
  • [Corporate] Home Banner

About Theranexus

Theranexus is a biopharmaceutical company that develops drug candidates to be used in the treatment of central nervous system (CNS) disorders. Theranexus' unique, patented technology is aimed at increasing the efficacy of CNS drugs that have already been approved and are available on the market.

Theranexus' technology is protected, unique, scalable and versatile, and used to generate high value-added proprietary drug candidates for different conditions, while reducing time-to-market and market entry costs and risks in comparison with standard drug development processes.



THERANEXUS presents an update on the progress of its main programs and announces its cash position as of 31 December 2020

18/01/2021
Download PDF File (538Ko)

THERANEXUS, Lyon Neuroscience Research Center and CERMEP announce the creation and funding of new joint public/private laboratory “Neuroimaging for Drug Discovery” (NI2D)

18/12/2020
Download PDF File (428Ko)

The Food And Drug Administration (FDA) issues a favorable opinion on the preclinical development plan submitted by THERANEXUS and BBDF

19/11/2020
Download PDF File (318Ko)

Presentation of the results of the phase 1b clinical study of THN201 for Alzheimer’s disease at the Clinical Trials on Alzheimer’s Disease conference (CTAD)

04/11/2020
Download PDF File (605Ko)

THERANEXUS and BBDF obtain European "orphan medicinal product" designation for BBDF-101 in Batten disease

21/10/2020
Download PDF File (290Ko)